<DOC>
	<DOC>NCT02647515</DOC>
	<brief_summary>To determine the efficacy of intravitreal ranibizumab injection as adjuvant therapy in the treatment of postvitrectomy diabetic vitreous hemorrhage (PDVH) accompanied by neovascular glaucoma (NVG) as a means of preventing recurrent vitreous hemorrhage （VH） and optimizing postoperative intraocular pressure（IOP）control.</brief_summary>
	<brief_title>Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Glaucoma, Neovascular</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>age≥18 years PDVH obscuring the disc and vessels for more than 14 days and no evidence of retinal detachment after primary vitrectomy for PDRrelated complications such as nonclearing VH, maculainvolving or maculathreatening tractional retinal detachment, or fibrovascular proliferation with vitreoretinal adhesions NVG occurred following PDVH less than 4 weeks (NVG was diagnosed when an IOP elevation of 22mmHg or more was accompanied by neovascularization of the iris and/or the anterior chamber angle) intraoperative use of longacting gas or silicone oil in primary vitrectomy, repeat vitrectomy after primary vitrectomy for retinal diseases other than VH, previous history of vitrectomy previous intravitreal injection of ranibizumab or bevacizumab in either eye previous intravitreal corticosteroids injection in either eye pregnancy or current oral contraceptive intake usage of clopidogrel bisulfate or coumadin uncontrolled hypertension and cardiac disease uncontrolled renal or liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>